BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
How one man's concern saved his brothers from heart disease- Ancient Egyptian pharaoh's boat is being reassembled in public at the Grand Egyptian Museum
- Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
- 'Pluribus' release date: Everything you need to know about the new series from 'Better Call Saul's' co-creator
- 5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- Collins Foods to offload 20 Taco Bell outlets in Australia
- Honda’s Biggest Flex Isn’t Its Superbikes, It’s Selling 500K Bikes In One Month
- The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
- The Fate of Mechanical technology: 5 Headways Forming Tomorrow
